News|Articles|September 24, 2014

Herpes Zoster Rash

Fluid-filled blisters; necrobiosis lipoidica; gestational diabetes mellitus . . . Test your knowledge on these and other subjects in this quiz.

Question 1:

NEXT QUESTION »

For the discussion, click here.

For the answer, click here.

Question 2:

NEXT QUESTION »

For the discussion, click here.

For the answer, click here.

Question 3:

NEXT QUESTION »

For the discussion, click here.

For the answer, click here.

Question 4:

Several brown, dry, asymptomatic plaques developed on the legs of a 59-year-old woman with diabetes mellitus and pulmonary sarcoidosis. The diagnosis was necrobiosis lipoidica.

NEXT QUESTION »

For the discussion, click here.

For the answer, click here.

Question 5:

ANSWER KEY »

For the discussion, click here.

ANSWER KEY:

Question 1. G

Question 2. B

Question 3. D

Question 4. F

Question 5. A

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Latest CME

Virtual Event

Missouri Oncology Society

2 Sessions are Available!

Virtual Event

Wisconsin Association of Hematology and Oncology

2 Sessions are Available!

Herpes Zoster Rash

Related Content

FDA Expands Roflumilast Cream 0.3% Approval for Plaque Psoriasis in Children Aged 2 Years and Older

FDA Approves Risankizumab for Pediatric Psoriasis, Psoriatic Arthritis

FDA Expands Teplizumab Approval for Pediatric Stage 3 Type 1 Diabetes

Zasocitinib Tops Deucravacitinib for Skin Clearance in Phase 3 Psoriasis Trial

AHA, ACC Issue First Clinical Guideline for CKM Syndrome

Latest CME

Missouri Oncology Society

Wisconsin Association of Hematology and Oncology

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

South Carolina Oncology Society

Minnesota Society of Clinical Oncology

West Virginia Oncology Society

North Carolina Oncology Association

Establishing the Rationale for ADC and ICI Combinations in TNBC

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Wyoming State Oncology Society

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Radioligand Therapy 101: The Science Behind the Strategy

Pathways to Progress: RAS in GI Cancers (Spotlight CE Session)

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

26th Annual International Lung Cancer Congress

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Patient, Provider, and Caregiver Connection™: Individualizing Care in C3 Glomerulopathy – Understanding Patient Challenges and the Role of Innovative Treatment

Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

ISGIO 2025: Pancreatic and Neuroendocrine Tumors

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Cases and Conversations™: Navigating CKD and Heart Failure in T1D and T2D—Applying the Latest Guidelines and Evidence

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Louisiana Oncology Society

New Mexico Society of Clinical Oncology

25th Annual International Congress on the Future of Breast Cancer® East

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Southern California Psychiatry Conference

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

Arkansas Association of Cancer Professionals

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Kentucky Society of Clinical Oncology

27th Annual International Lung Cancer Congress®

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Looking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease